DocWire News Editors

DocwireNews

Information on costs related to the treatment of acute bleeding events in patients with hemophilia A is lacking, so researchers evaluated the healthcare resource utilization and costs associated with this area of treatment. The results of the study were presented at the AMCP Annual Meeting during a poster session titled “Healthcare Resource Utilization and Costs Associated with Treatment of Acute Bleeding Events Among Patients with Hemophilia A in the United States.”
The retrospective, observational study used data from 29 U.S. hematologists, including medical charts for patients with hemophilia A who experienced one acute bleeding event requiring an outpatient, emergency room, and/or inpatient visit between 2015 and 2017.
Researchers assessed patient characteristics and detailed healthcare resource utilization information during bleeding events (e.g., type of visit, procedures and tests performed, medications administered). They estimated costs by applying utilization information to unit prices from publicly available data sources; and costs per acute bleeding event were summarized by presence or absence of inhibitors at the time of the bleeding event.
A total of 180 bleeding events occurred—114 with inhibitors at the time of the event and 66 without—among 143 patients. Thirty-seven percent required at least one hospitalization, 33% required at least one emergency room visit, and 38% required at least one outpatient visit.
The median total medical and medication costs to treat a bleeding event was $18,949 (mean, $44,119; standard deviation [SD], $55,614) for patients with inhibitors and $5,616 (mean, $30,051; SD, $39,803) for patients without inhibitors.
Excluding medications—such as factor VIII and bypassing agents—the median medical cost for treating a bleeding event was $180 (mean, $29,498; SD, $41,466) for patients with inhibitors and $137 (mean, $25,160; SD, $37,881) for patients without inhibitors.
“These study findings demonstrated substantial costs associated with treatment of acute bleeding events in patients with hemophilia A…[and] also highlight the unmet need for effective therapies to prevent acute bleeding [in these patients],” the researchers concluded.
The study was sponsored by Genentech.
Song J, Chamberlain C, Rokito A, Cammarota J, Ma E, Xu Y, Betts K. Healthcare Resource Utilization and Costs Associated with Treatment of Acute Bleeding Events Among Patients with Hemophilia A in the United States. Abstract D6. Presented at the AMCP Managed Care &amp; Specialty Pharmacy Annual Meeting, April 23-26; Boston, MA.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Substantial Costs Associated With Acute Bleeding Events in Hemophilia A

AMCP 2018

Information on costs related to the treatment of acute bleeding events in patients with hemophilia A is lacking, so researchers evaluated the healthcare resource utilization ...

Substantial Costs Associated with Acute Bleeding Events in Hemophilia A

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe